Wird geladen...
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma
Proteasome inhibitor bortezomib is an effective therapy for relapsed and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance can limit its long-term utility. Recent research has focused on targeting ubiquitin receptors upstream of 20S proteasome...
Gespeichert in:
| Veröffentlicht in: | Leukemia |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5749253/ https://ncbi.nlm.nih.gov/pubmed/27118409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.97 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|